Drug intelligence / Profile preview

NKT-1992

Development stage: Preclinical
Lead developer: NiKang Therapeutics
Modality: Small Molecules

Overview

NKT-1992 is an investigational small-molecule antiviral agent discovered by NiKang Therapeutics using structure-based design and licensed to Hansoh Pharma for development and commercialization in China. It targets a highly conserved enzymatic domain that is critical for viral transcription and replication, with the aim of rapidly reducing viral load and improving associated signs and symptoms of infection.[4][5] NKT-1992 remains in preclinical development, and detailed target identity, indication focus, and clinical data have not yet been publicly disclosed.[4][5]

Beyond the preview

Go deeper on NKT-1992.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKT-1992.

Explore the full profile